Explore
the science that supports OC-Auto FIT
Healthy people. Healthy communities.
A large study evaluated the impact of regular screening with OC-Auto FIT across 4 million members of one health plan. The study evaluated screening participation, incidence, and number of deaths resulting from colon cancer over a 15-year period.1
The study found that offering OC-Auto FIT resulted in:
43%
25.5%
52.4%
more patients participating in regular colon cancer screening1
fewer cases of colon cancer in the population, due to early detection of pre-cancerous polyps1
fewer deaths due to colon cancer1
“The fecal immunochemical test product [by Polymedco] is the FIT test with the best clinical evidence to support its use.”2
Dr Douglas Rex, past President of the American College of Gastroenterology (ACG)
Saving more lives through early detection
Every year, millions of patients and healthcare providers around the world rely on OC-Auto FIT for annual screening3
Getting OC-Auto FIT is easy.
If you are between the ages of 45 and 75 and of average risk*, be sure to ask your healthcare provider about annual screening with OC-Auto FIT, or order a kit for yourself today.
*Professional guidelines recommend regular colon cancer screening for all average-risk adults between 45-75 years of age.4-6 For screening purposes, you are at average risk of colorectal cancer if you do not have a personal history of colorectal cancer or certain types of polyps; a family history of colorectal cancer; a confirmed or suspected hereditary colorectal cancer syndrome, such as familial adenomatous polyposis (FAP) or Lynch syndrome (hereditary nonpolyposis colon cancer or HNPCC); a personal history of inflammatory bowel disease (ulcerative colitis or Crohn’s disease); or a personal history of abdominal or pelvic radiation for a previous cancer. Talk to your healthcare provider if you are not sure if you are at average or increased risk of colorectal cancer.7
OC-Auto Sensor io iFOB Test is designed to be used together as an immunoassay test system. The test system is intended for the qualitative detection of fecal occult blood in feces by professional laboratories. The automated test is used for the measurement of fecal occult blood and is useful as an aid to detect blood in stool when lower gastrointestinal bleeding may be suspected.
References:
- Levin TR, Corley DA, Jensen CD, et al. Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population. Gastroenterology. 2018;155(5):1383-1391. doi:10.1053/j.gastro.2018.07.017
- Rex DK. Finding the best FIT for colorectal cancer screening. NEJM Journal Watch. June 13, 2013. Accessed February 19, 2024. https://www.jwatch.org/na31297/2013/06/13/finding-best-fit-colorectal-cancer-screening
- Data on file with Polymedco, Inc.
- US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Screening for colorectal cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238
- Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening 2021. Am J Gastroenterol. 2021;116(3):458-479. doi:10.14309/ajg.0000000000001122
- Rex DK, Boland CR, Dominitz JA, et al. colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on colorectal cancer. Am J Gastroenterol. 2017;112(7):1016-1030. doi:10.1038/ajg.2017.174
- Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guidelines update from the American Cancer Society. CA Cancer J Clin. 2018;68(4):250-281. doi:10.3322/caac.21457
